Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. INCY.NASDAQ

Incyte Corporation (INCY NASDAQ) stock market data APIs

$68.57 -0.04(-0.1%) as of July 26, 2024
Price chart is built with Anychart

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation

Incyte Corporation Financial Data Overview

68.61
68.57
-
69.85
68.2405
50.27-70.36
13 509 M
20.7788
197 M
3 768 M
0.735
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'INCY',
Type: 'Common Stock',
Name: 'Incyte Corporation',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000BNPSQ9',
ISIN: NULL,
CUSIP: NULL,
CIK: '879169',
EmployerIdNumber: '94-3136539',
FiscalYearEnd: 'December',
IPODate: '1993-11-04',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Incyte Corporation Fundamental Data is available in our Financial Data APIs

  • Net Revenue 3 768 M
  • EBITDA 802 M
  • Earnings Per Share 3.3
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Incyte Corporation Earnings via APIs

  • Latest Release 2024-07-30
  • EPS/Forecast 1.11

Get Incyte Corporation End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Incyte Corporation latest news via APIs

Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?

We expect Incyte Corporation INCY to surpass expectations when it reports second-quarter 2024 results on Jul 30, before the opening bell. Let’s see how things have shaped up for the quarter to be r...

Qiagen (QGEN) Expected to Beat Earnings Estimates: Should You Buy?

Wall Street expects a year-over-year decline in earnings on lower revenues when Qiagen (QGEN) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in...
Do you have any questions?
support@eodhistoricaldata.com